annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 7D Effect of GSK-3 inhibition in vitro and in vivo on antitumor effect of sorafenib
in renal cell carcinoma (RCC). (Abstract #4617)
H. Kawazoe, V. Bilim, K. Yuuki, S. Naito, A. Muto, Y. Tomita
Brd. 7E Detection of circulating tumor cells in patients with renal cell carcinoma
compared with a control group. (Abstract #4618)
T. Gutschi, O. Pachernegg, K. Lackner, G. C. Hutterer, R. Stauber, K. Pummer,
R. Zigeuner
Brd. 7F Correlation of regulatory T-cell levels and overall survival in metastatic renal
cancer patients treated with sunitinib-based therapy. (Abstract #4619)
E. Tartour, O. Adotevi, H. Pere, B. Beuselinck, J. Ayllon, J. Medioni, S. Oudard
Brd. 7G The effect of sunitinib on immune parameters and haemopoetic stem cell
markers in patients with untreated clear cell renal cancer. (Abstract #4620)
S. Chowdhury, T. S. O’Brien, N. Sarwar, J. Shamash, S. McGrath, S. Agrawal,
L. Lim, S. M. Rudman, P. G. Harper, T. Powles
Brd. 7H Fibroblast growth factor pathway in renal cell carcinoma. (Abstract #4621)
I. Tsimafeyeu, L. Demidov, H. Ta, E. Stepanova, N. Wynn
Brd. 8A Expression of enhancer of zeste homolog 2 in renal cell carcinoma and
relationship to downregulation of micro RNA-101. (Abstract #4622)
T. Sakurai, V. Bilim, K. Yuuki, M. Tsukigi, A. V. Ougolkov, Y. Tomita
Brd. 8B Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and
imatinib) on blood glucose levels in diabetic and non-diabetic patients in
general clinical practice. (Abstract #4623)
N. M. Agostino, V. M. Chinchilli, A. M. Koszyk-Szewczyk, R. Gingrich, J. M. Sivik,
J. J. Drabick
Brd. 8C Renal cell carcinoma in octogenarians: Comprehensive analysis using the
SEER database. (Abstract #4624)
N. J. Hellenthal, M. H. Hayn, H. L. Kim, W. Underwood III, T. Schwaab
Brd. 8D Single-fraction radiosurgery for treatment of spinal and cerebral metastases
from renal cell carcinoma under systemic tyrosine kinase inhibition.
(Abstract #4625)
M. D. Staehler, N. Haseke, P. Nuhn, C. Nordhaus, C. G. Stief, B. Wowra,
A. Muacevic
Brd. 8E Metastatic renal cell carcinoma (mRCC): Relationship between initial nonrenal
RECIST-target metastases hypoxia, change after 1 month of sunitinib,
and therapeutic response: An 18 F-MISO PET-CT study. (Abstract #4626)
F. Hugonnet, L. Fournier, S. Oudard, Hypoxia in Renal Cancer (HYRC) Multicentric
Group
Brd. 8F Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with
renal cell carcinoma. (Abstract #4627)
M. Schmidinger, M. Bojic, U. Vogl, W. Lamm, C. Zielinski
Brd. 8G Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor
(VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor
(b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in
metastatic renal cell carcinoma (MRCC): Biologic results from the
randomized phase II RAPSODY trial. (Abstract #4628)
S. Bracarda, V. Ludovini, C. Porta, C. Boni, A. Santoro, D. Gasparro, E. Cortesi,
V. De Angelis, M. Sisani, L. Crinò, GOIRC Group
Brd. 8H Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in
predicting treatment-induced hypertension (HTN) and clinical outcome (CO)
in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib.
(Abstract #4629)
J. J. Kim, S. A. Vaziri, P. Elson, B. I. Rini, A. Patel, N. S. Basappa, M. Ganapathi,
R. Ganapathi
363
MONDAY